Stockreport

TG Therapeutics Announces Publication of Ublituximab Phase 2 Clinical Trial Results in Multiple Sclerosis Journal

TG Therapeutics, Inc.  (TGTX) 
Last tg therapeutics, inc. earnings: 11/12 07:34 am Check Earnings Report
US:NASDAQ Investor Relations: ir.tgtherapeutics.com
PDF Ublituximab was generally well tolerated across all cohorts including those patients receiving one-hour infusions for the 450mg dose currently being studied in the Phase [Read more]